Strategic Plan 2023-25
CONTENTS

Executive Summary .................................................. 3
Consilium Scientific Purpose .................................... 5
Consilium Scientific Vision ....................................... 6
Consilium Scientific Values ....................................... 7
Strategic Priorities at a Glance ............................... 8
Objectives and Activities ....................................... 10
Income Projections ............................................... 15
Appendix A. Consilium Scientific Governance .......... 17
EXECUTIVE SUMMARY

Clinical research fails patients, scientific progress, and our society when its purpose, structure and execution are sub-optimal. Consilium Scientific has been established to raise awareness of how these challenges can be overcome and change the status quo.

Patients deserve better clinical research

This aspiration is an ambitious undertaking. It requires the work of many committed organisations and individuals to gradually bring changes to the system by setting shared goals and joining forces to achieve them. Consilium Scientific strives to become a leader and an umbrella organisation for the groups and individuals taking on this mission.

Over the past three years, Consilium Scientific has operated as a non-profit start-up, developing its initial services and competencies. We have built a highly proficient and dedicated team. In 2020, we established a successful internship programme for MSc graduates in Health Policy from the London School of Economics and a bi-weekly seminar series that included 15 events and 47 seminars delivered by 84 speakers.

Consilium Scientific has developed Health on Trial, a service which provides in-depth analytics on registered clinical trials. Health on Trial brings insights to research funders and advocacy groups supporting them to improve clinical research standards in their field. To date, three projects have been delivered for Myeloma Patients Europe and Motor Neurone Disease patient organisations. In 2022, Consilium Scientific incorporated TranspariMed, a campaign for clinical trial reporting. We are actively engaged with policy work in-house and through the support of like-minded organisations.

In November 2022, we appointed a distinguished Board of Trustees and a highly competent Advisory Board. Supported by a committed team, we are setting the organisation on a path for successful operations and growth.

This document presents Consilium Scientific’s strategic plan for three years (2023-2025) to establish the organisation as a professionally operating entity and to put it on the map as a critical player in the clinical research policy eco-system. This strategic plan will deliver key activities to establish Consilium Scientific as a non-profit organisation dedicated to policy change. We will empower like-minded groups to provide evidence, advocacy, education and other interventions to improve clinical research.
Over the next three years, Consilium Scientific will focus on four strategic priorities that will shape the organisation’s mission of improving quality in clinical research:

1. **Awareness**: identifying routes for effective awareness raising
2. **Acceptance**: achieving support for the need for change
3. **Action**: delivering and enabling interventions to improve clinical trials
4. **Capacity**: building an efficient non-profit organisation

Consilium Scientific’s Board of Trustees and staff are committed to initiating and sustaining fundraising, tackling challenging organisational and systemic issues, and addressing operational and political challenges. Progress on the strategic plan will be monitored quarterly, with course corrections made as necessary. Our goal is to develop Consilium Scientific into an influential, viable and reputable leader in clinical research policy.
PURPOSE

• Create a platform for initiatives and individuals to collaborate in improving the quality of clinical research

• Drive change in attitudes and practice in clinical research through education and advocacy

• Campaign for policy changes that will increase the value of clinical research for patients and society
VISION

Patients Deserve Better Clinical Research
VALUES

Core values represent the lens through which all decisions and activities are viewed and considered at Consilium Scientific

INDEPENDENCE
We are politically and financially independent

RIGOUR
The methods we apply in our work are based on scientific rigour
We only work with groups and individuals adhering to this principle

TRANSPARENCY
Our methods and outputs are in the public domain. We expect our collaborators to maximise the transparency of their work
STRATEGIC PRIORITIES AT A GLANCE

Consilium Scientific identifies four strategic planning priorities that support its purpose

1. AWARENESS

Many organisations, researchers and activists are working on improving quality in clinical research however, these efforts are often disjointed, under-resourced, and patchy. At times, important work on integrity in clinical research does not receive deserved attention and does not lead to policy change. Compared, for example, to climate change, there is no public awareness of the problems in clinical research. Even among stakeholders involved in clinical research, the understanding is patchy.

There are many approaches to raising awareness. Their effectiveness will vary based on the audience, the means of communication, and resources. To address this strategic priority in the next three years, we will create an infrastructure within Consilium Scientific to effectively implement awareness raising activities among decision-makers and pilot campaigns to identify ways that work and do not work. Disseminating the LUPA project outputs (see 3. Action) will be our leading awareness-raising initiative.

2. ACCEPTANCE

We want to help create a world where clinical research realises its full potential. This can only be achieved if those who fund, undertake and use clinical research are aware of and commit to tackling the issues that currently prevent that potential from being realised. Achieving alignment on potential solutions will then become possible.

To address this strategic priority, Consilium Scientific will directly engage with key stakeholders in the life sciences industries, patient organisations, the research community, funders of clinical research, CROs, policy- and decision-makers. We will devise paths which lead to alignment and convergence for actions that can decrease research waste. The process will include interviews, surveys, debates, Delphi panels, evidence generation through primary and secondary research, advocacy and policy change initiatives.

*The LUPA project – mapping of problems and initiatives looking at solving them in clinical research
3. ACTION

Consilium Scientific will promote and implement strategic initiatives to enhance Awareness and Acceptance. The project to be delivered in the next three years is a state-of-the-art evidence generation initiative called LUPA to map out problems in clinical research, their complexity and magnitude, from the perspective of all stakeholders. As part of this work, Consilium Scientific will investigate and catalogue the issues and identify those that have been quantified. Consilium Scientific will identify the groups and individuals working to address these problems to understand where there are gaps and propose solutions for the most pressing issues.

Research and policy work conducted by Consilium Scientific will ensure that the organisation represents a competent and leading player in the field – a ‘go-to place’ for information on addressing problems in clinical research. Consilium Scientific will expand its clinical trials analytics work through its Health on Trial platform and Trials Finder service.

We will lay the foundation for the Consilium Scientific Incubator, the aim of which will be to bring together organisations and individuals working towards solving problems in clinical research in a rich environment enabling collaboration and joint action. Consilium Scientific will lead by example in its advocacy, policy change, and education initiatives making a difference, one win at a time.

4. CAPACITY

In the next three years, Consilium Scientific will build a sustainable organisation with appropriate resources to support internal operations. This will enable us to undertake the activities supporting other players in the system, who are working to address problems in clinical research and bring about relevant policy changes.

Doing so will require a focus on fundraising campaigns and project work to ensure sufficient funds to support current operations and to invest in organisation’s development. A robust and executable business plan will be the backbone of the organisation’s activities and accountability. We will attract high-calibre professionals, build an inspirational and rewarding working environment for our team, develop internal processes and prepare the organisation for growth to make an impact in the decades to come.

Consilium Scientific will aim to gain a charitable status in the UK in 2023-24.
OBJECTIVES & ACTIVITIES
**1. AWARENESS**

<table>
<thead>
<tr>
<th>OBJECTIVES</th>
<th>ACTIVITIES</th>
</tr>
</thead>
</table>
| 1.1 Create an infrastructure within Consilium Scientific to implement awareness activities effectively | a) Explore options for increasing awareness  
b) Identify partners and contractors that can help with the delivery of awareness activities  
c) Raise funds for these awareness-raising activities |
| 1.2 Pilot awareness campaigns to identify approaches that work with different groups | d) Using evidence at Consilium Scientific’s disposal (in-house outputs or work of partners and contractors), set up pilots delivering information in different ways and formats - employ strategies identified in activity a) |
## 2. ACCEPTANCE

<table>
<thead>
<tr>
<th>OBJECTIVES</th>
<th>ACTIVITIES</th>
</tr>
</thead>
</table>
| 2.1 Identify approaches which are effective in improving acceptance of problems in clinical research: helping stakeholders find a common goal and common ground to work towards solutions | a) Engage with stakeholders to learn which approaches resonate with different groups  
  b) Raise funds for activities and preparatory work aimed at establishing acceptance of the issues at play, and alignment on potential solutions |
| 2.2 Pilot initial acceptance enabling approaches among different stakeholders | c) Based on the results of activities under objective 2.1, select and pilot approaches with different stakeholders recording measurable impacts |
## 3. ACTION

<table>
<thead>
<tr>
<th>OBJECTIVES</th>
<th>ACTIVITIES</th>
</tr>
</thead>
</table>
| **3.1 Enhance Consilium Scientific’s track record as an innovator in improving evidence generation** | a) Deliver on already established Consilium Scientific activities (such as Health on Trial, TranspariMed)  
  b) Develop evidence base for problems and solutions in clinical research across all stakeholders (The LUPA project)  
  c) Create a dynamic online tool to keep the evidence on problems and solutions in clinical research up to date |
| **3.2 Set up Consilium Scientific Incubator: Bring together and enable successful operations of like-minded individuals and organisations** | d) Establish a fund for supporting like-minded organisations working to decrease waste in clinical research  
  e) Establish the infrastructure and processes for the operations of the Incubator  
  f) Ensure that the work/collaborations of supported organisations and individuals are aligned with the Consilium Scientific’s purpose and vision |
| **3.3 Lead by example through impactful policy and advocacy work**         | g) Deliver high-quality policy /advocacy work through its campaigns (TranspariMed)  
  h) Establishes connections with key players and decision-makers  
  i) Raise funds for TranspariMed’s work |
| **3.4 Deliver successful networking, educational and training opportunities** | j) Internship programme  
  k) Policy forum  
  l) Workshops and seminars  
  m) Educational courses |
## 4. CAPACITY

<table>
<thead>
<tr>
<th>OBJECTIVES</th>
<th>ACTIVITIES</th>
</tr>
</thead>
</table>
| 4.1 Develop a sustainable business plan which sets Consilium Scientific for growth whilst maintaining its non-profit status | a) Create a detailed business plan for Consilium Scientific 2023-25  
b) Generate income for Consilium  
c) Put in place organisational processes |
| 4.2 Enable a rewarding working environment for our staff | d) Ensure each staff member is appropriately compensated for their work  
e) Ensure our staff receive appropriate training (internal/external)  
f) Ensure our staff are given opportunities to maximise their potential and realise their ambitions  
g) Provide opportunities for staff engagement in the organisation’s planning – keep our staff up to date on Consilium Scientific’s performance and strategic initiatives |
| 4.3 Empower the Board of trustees to support Consilium Scientific in achieving organisational goals and objectives | h) Keep the Board adequately informed and engaged  
i) Engage with Advisory Board to help Consilium achieve its strategic priorities |
INCOME PROJECTIONS
### Income projections:

<table>
<thead>
<tr>
<th>Source of Income</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fee for Service: Health on Trial, Trials Finder projects</td>
<td>£55,000</td>
<td>£60,000</td>
<td>£80,000</td>
</tr>
<tr>
<td>TranspariMed campaign</td>
<td>£30,000</td>
<td>£40,000</td>
<td>£45,000</td>
</tr>
<tr>
<td>Fundraising for LUPA/other Philanthropy</td>
<td>£200,000</td>
<td>£400,000</td>
<td>£178,000</td>
</tr>
<tr>
<td>Consilium Scientific Crowdfunding online</td>
<td>£5,000</td>
<td>£7,000</td>
<td>£10,000</td>
</tr>
<tr>
<td>Seminars</td>
<td>£5,000</td>
<td>£10,000</td>
<td>£12,000</td>
</tr>
<tr>
<td>Events and Education</td>
<td>n/a</td>
<td>£5,000</td>
<td>£10,000</td>
</tr>
<tr>
<td>Grants beyond TranspariMed work</td>
<td>n/a</td>
<td>£30,000</td>
<td>£100,000</td>
</tr>
</tbody>
</table>

### Projected Source of Income:

- **2023**
  - Philanthropy: 70%
  - Grants: 8%
  - Online Donations: 3%
  
- **2024**
  - Philanthropy: 76%
  - Fee for Service: 19%
  - Grants: 11%
  - Online Donations: 3%
  
- **2025**
  - Philanthropy: 44%
  - Fee for Service: 18%
  - Grants: 35%
  - Online Donations: 3%
Appendix A: CONSILIUM SCIENTIFIC GOVERNANCE / 2023–2025

TRUSTEES

Eric Low (Chair)

Sir Andrew Dillon

Prof John Hickman

Dr Martin Kaiser

ADVISORY BOARD

Kalipso Chalkidou, MD, PhD

Michael Kolodziej, MD

Francois Maignen, PharmD, MSc

Lydie Meheus, PhD

Jack Scannell, PhD

Professor Ian Tannock, MD, PhD